• Top
• Background
• Methods
• Summary of re...
• Conclusion

This article is part of the supplement: Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection .

Poster presentation

Efficacy and safety of tenofovir/emtricitabine compared to abacavir/lamivudine in HIV-1 infected patients in clinical setting. The TEAL study

KJ Eccleston¹, A Bambumba¹, CS Babu¹, S Ahmed² and V Lee¹

¹Central Manchester and Manchester Childrens University Hospitals NHS Trust, Manchester, UK

²University Hospitals of South Manchester NHS Trust, Manchester, UK

corresponding author email

from Ninth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 9–13 November 2008

Journal of the International AIDS Society 2008, 11(Suppl 1):P79doi:10.1186/1758-2652-11-S1-P79

The electronic version of this abstract is the complete one and can be found online at: http://www.jiasociety.org/content/11/S1/P79

Published:

10 November 2008

© 2008 Eccleston et al; licensee BioMed Central Ltd.

Background

Limited direct comparative data exist between the recommended dual NRTI fixed dose combinations, tenofovir/emtricitabine (Truvada) and abacavir/lamivudine (Kivexa). A recent study (HEAT) evaluated these dual NRTI backbones with a boosted PI. However, there are no data comparing these two formulations when used with other antiretroviral drugs.

Methods

Retrospective study of HIV-1 infected patients in two Genito-Urinary Medicine clinics. Patients taking either Truvada or Kivexa were included. Data including previous treatment, resistance test, HLA B5701 status, pre-treatment CD4 count, plasma viral load, age, ethnicity, renal function, lipid profiles were gathered. Primary endpoint was the proportion of subjects with viral load <50 copies/ml at 48 weeks.

Summary of results

232 patients were included, of which 129 were on Truvada and 103 on Kivexa; 114 were treatment naive. (Tables 1 and 2.)

Conclusion

Truvada was non-inferior to Kivexa in this cohort. However, virological failure was observed in three patients when Kivexa was used with an NNRTI. Median CD4 increase was greater in Truvada arm at 48 weeks but this was not statistically significant. Further data will be presented at the meeting.

Have something to say? Post a comment on this article!